2025全年：收入32.6亿-32.9亿美元（先前？实际为34.1亿-34.4亿美元？注意：原文CFO说“revenue in a range of $3.41 billion to $3.44 billion”，已更新范围），有机收入下降4%-5%，收购贡献约3.5%，外币顺风约2.5%，报告收入增长1%-2%。非GAAP EPS 1.85-1.90美元（含MCP稀释0.07美元）。营业利润率同比下降约250个基点（M&A 60bps，关税60bps，外汇65bps，有机65bps）。
“Q3 order performance was quite a bit better than expected and represents a meaningful sequential step-up from our Q2 performance.” (CEO)
“While one quarter of improved orders is too early to call a trend, we are encouraged that our two divisions most directly tied to macroeconomic factors… saw strong bookings in Q3.” (CEO)
“Our third quarter P&L was still impacted by the various headwinds… However, the results came in ahead of our expectations.” (CEO)
“Our Q3 results came in above our expectations on both the top and bottom lines.” (CFO)
“We are updating our full year 2025 forecast… to reflect Q3 results, order timing and the impact of our September mandatory convertible preferred offering.” (CFO)
Prepared Metrics
Metric
Value
Speaker/Context
Q3 2025报告收入
8.605亿美元
CEO
Q3 2025有机收入增长
-4.5%
CEO
Q3 2025非GAAP营业利润率
12.3%
CEO
Q3 2025非GAAP稀释EPS
0.45美元
CEO
Q3 2025 BSI书单比率
>1.0x
CEO
2025全年有机收入增长指引
-4%至-5%
CFO
2025全年非GAAP EPS指引
1.85-1.90美元
CFO
2025全年报告收入指引
34.1亿-34.4亿美元
CFO
Q&A Batch (1-5 of 9)
Q1 — Puneet Souda
Topic: Q4 order momentum and geographic/end-market breakdown
Key points:
No Q4 data yet; too early to comment.
ACA/GOV order strength in Q3 was primarily outside the U.S.; U.S. ACA/GOV orders improved sequentially (Q3 vs Q2) but were not a growth driver year-over-year.
Biopharma orders improved in Q3, particularly in the U.S.; applied market strength had broad international distribution.
GigaHertz NMR: no revenue in Q3; one order expected in Q4 (non-U.S.); Q3 organic decline partly due to >EUR 25 million revenue from two GigaHertz systems in Q3 2024.
Mgmt stance: Neutral — cautious on extrapolating Q3 trends; needs Q4 orders to give 2026 guidance.
Q2 — Avantika Dhabaria
Topic: Government shutdown impact and 2026 revenue outlook
Key points:
Government shutdown not formally baked into Q4 guidance; assumes minor effect so far; a multi-week shutdown could delay grants, orders, and installations.
No formal 2026 revenue guidance; needs Q4 2025 bookings to give reliable guidance in February 2026.
Even without growth, cost cutting can expand operating profit margins by 250–300 bps; expects double-digit non-GAAP EPS growth next year, absorbing ~$0.20 dilution from mandatory convert.
Mgmt stance: Neutral — no revenue assumption for 2026; margin expansion and EPS growth achievable even with flat top line.
Q3 — Tycho Peterson
Topic: Margin expansion assumptions, NIH budget, China stimulus, order pushout
Key points:
Not confirming a specific margin expansion number (e.g., 300 bps); driving toward high end of $100M–$120M cost savings target to increase confidence in significant margin expansion and double-digit EPS growth.
NIH budget flush in Q3 (especially September) improved funding; U.S. academic orders improved sequentially but not year-over-year; not assuming flat NIH/NSF budget for 2026 — can work with 10%–15% down.
China stimulus-related orders were less than $10 million (closer to $6 million) in Q3; green shoot vs zero in Q2.
Some revenue pushout from Q4 to Q1 due to customer delivery preferences; most large orders booked in September will be revenue in 2026.
Mgmt stance: Bullish on margin expansion capability; neutral on NIH/China outlook — needs Q4 clarity.
Q4 — Luke Sergott
Topic: China stabilization and spatial biology demand
Key points:
China Q3 felt a little better sequentially (including ~$6M stimulus green shoots); Q4 exit rate not indicative of 2026 due to weak P&L from prior orders and currency/tariff challenges.
Spatial biology: orders improved in Q3 (both consumables and instruments); CosMx and CellScape doing well; PainScape still early; 2/3 of spatial business is academic/government, 1/3 biopharma.
Mgmt stance: Neutral on China — hesitant to read Q4 as trend; bullish on spatial biology improvement.
Q5 — Subhalaxmi Nambi
Topic: Diagnostics and semi outlook; order strength by product
Key points:
Diagnostics (ELITech, clinical microbiology) >$500M revenue; ELITech growing high single digits in 2025; placements of InGenius/BeGenius stations >20% ahead of business plan; revenue ramp takes ~6 months.
Semi ~$300M annual revenue; flattish in 2025; expects improvement in 2026; has some of the best incremental margins.
Q3 order strength came from larger ASP instruments (not diagnostics); driven by ACA/GOV outside U.S., biopharma, and applied markets.
Mgmt stance: Bullish on diagnostics (placement momentum, margin expansion); neutral on semi (annual view needed).
Q&A Batch (6-9 of 9)
Q6 — Casey Woodring
Topic: 4Q order seasonality and backlog duration
Key points:
ACA/GOV catch-up in 3Q was observed in the U.S. and China, but not in rest of world; Q2 orders in those geographies were weak due to holding back.
Q4 orders are "always strong" sequentially versus Q3; the uncertainty is year-over-year trend versus Q4 of last year.
Backlog at end of Q3 2025 is about 7 months, up from 6.5 months at end of Q2; based on guidance, considerable backlog will carry into 2026.
Mgmt stance: Neutral (Q4 sequential improvement is a given, but year-over-year comparison and backlog drawdown depend on 4Q revenue performance).
Q7 — Brandon Couillard
Topic: Interest expense run rate and share count from MCP offering
Key points:
Impact on share count from MCP offering is roughly 13 million shares (confirmed "yes").
Interest expense modeling is complicated due to foreign exchange gains in that line; specific numbers were not provided but will be discussed in future modeling discussions.
Mgmt stance: Neutral (no specific figure given; deferred to later modeling discussions).
Q8 — Joshua Waldman
Topic: Europe order strength and pharma investment trends
Key points:
Europe was stronger in both ACA/GOV and applied/biopharma; no specific one-off funding programs drove the trend, increasing confidence but requires 4Q order confirmation.
Biopharma orders globally were strong in 3Q on a revenue basis; management sees no particular year-end push for orders.
Biopharma investment is viewed as post-COVID hangover clearing, with focus on tools for deeper disease biology and drug discovery (Bruker’s core offering).
Mgmt stance: Cautiously bullish on Europe (no one-offs noted); neutral on pharma (no urgency for year-end orders, but structural investment thesis intact).
Q9 — Douglas Schenkel
Topic: Cost-savings initiatives, margin expansion timing, and 2026 targets
Key points:
Cost-saving initiatives expected at high end of $100 million–$120 million range for FY2026; 95% of actions already underway or fully implemented.
Margin expansion of "closer to $300 million" is the expectation even under relatively weaker revenue conditions for 2026.
Delay in savings hitting P&L likely in Q2 2026 (not Q1) due to European regulatory processes; Q1 will have ~90%–95% of run rate cost savings implemented.
4Q 2025 has mix challenges affecting organic operating margin guidance, explaining the recent headwind increase of 45 basis points.
Mgmt stance: Bullish (fully committed to $120 million cost savings; margin expansion target holds even in flat growth; good cooperation from European works councils).